Bevacizumab(Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review

Trial Information

Bevacizumab(Avastin) Induced Hypertension and Correlation With Tumor Response, a Chart Review

This study is a retrospective chart review of all patients with metastatic cancer of any
type treated with bevacizumab(with or without chemotherapy) at the University of New Mexico
Cancer Research & Treatment Center within the last year to investigate if there is a
correlation between bevacizumab induced hypertension and response rates. We will look at a
wide variety of tumor types with a planned subset analysis to evaluate these correlations
within individual tumor types. As mentioned above, Grades of bevacizumab induced
hypertension is typically reported according to the NCI common terminology criteria for
adverse events which will be included in our study but in addition we will also evaluate for
incremental changes in systolic(SBP), diastolic (DBP), and mean arterial blood(MAP)
pressures in mmHg. Looking at these three variables will allow us to see if there is one
component (SBP or DBP) or a combination of both (MAP) that may allow us to predict response.
Response will be measured by appropriate radiographic imagine (CT scan or x-rays) and/or
appropriate tumor markers. In addition, as VEGF appears to play a role in hypertension, we
would like to look at pre-existing hypertension as a predictor for response and/or
bevacizumab induced hypertension.